Sweet FA? Siemens voices eleventh-hour concern over UK procurement review
This article was originally published in Clinica
As the UK government prepares to unveil next week the results of a root-and-branch review of medtech procurement (www.clinica.co.uk, 13 February 2013), key imaging player Siemens Healthcare has renewed industry warnings against the “inappropriate deployment” by NHS Trusts of framework agreements.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.